Regulators of Cognition Affect and Psychosis Drugs: A Paradigm Shift in Antipsychotic Drug Terminology

The term “antipsychotic” has served psychiatry for over 70 years, originating during an era when psychosis was viewed as the central and defining disorder of serious mental illness. However, our understanding of both psychiatric disorders and the pharmacology of their treatments has advanced significantly. Medications historically labeled as “antipsychotics” now show proven efficacy in treating a broad range of symptoms beyond psychosis, including mood instability, cognitive deficits, and functional impairments. Despite their diverse pharmacological action, ranging from dopamine D2 antagonism to partial agonism and serotonin modulation and now central cholinergic action, the term “antipsychotic” remains entrenched in clinical language, often misrepresenting both mechanism and therapeutic intent. Moreover, the term carries sociolinguistic consequences, contributing to patient resistance and stigma, particularly when used in populations who do not identify as psychotic. This article reviews the historical origins of antipsychotic nomenclature, summarizes the evolution of drug mechanisms, including emerging targets like acetylcholine, and examines the impact of terminology on clinical engagement. We propose that the current term be replaced, or at least supplemented, by a nomenclature that aligns more closely with contemporary pharmacology and patient-centered care, as supported by a targeted review of the literature on nomenclature and stigma in psychiatric pharmacology. The concept of “regulators of cognition, affect, and psychosis drugs,” classified by receptor action and therapeutic goal (such as dopamine stabilizers, thought organizers, and mood optimizers), offers a more accurate and humanistic framework. Such reform is necessary to promote adherence, reduce stigma, and reflect the evolving scientific landscape of psychiatric treatment.